StockData
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. (PYXS) stock

PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.81+0.13 (+7.74%)

Close on Nov 20, 2026Market cap $150.97MP/E –Yield –

Pyxis Oncology gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Pyxis Oncology's gross profit for the twelve months ending Dec 31, 2024 was $15.67M. For fiscal 2025 it was $11.47M, down 26.8% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.47M-26.8%
FY2024Dec 31, 2024$15.67M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0–
Q1 FY2024Mar 31, 2024$15.67M–

More Pyxis Oncology figures

See a number that looks wrong?